• Perrigo swung to a third-quarter loss from continuing operations of $0.10 per diluted share from a year-earlier profit.
• Net sales fell 5% year over year to $988.6 million, partly reflecting divestitures and lower Infant Formula sales.
• The planned Infant Formula divestiture carries consideration of up to $175 million, including $40 million in upfront cash.
• A related impairment loss of $275 million to $375 million is expected in the fourth quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perrigo Company plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611040630PR_NEWS_USPR_____DE88164) on November 04, 2026, and is solely responsible for the information contained therein.